NCT00644969View on ClinicalTrials.gov

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Smoking Cessation
Interventions
DRUG

placebo

Randomization 2:1 treatment to placebo

DRUG

varenicline (CP-526,555)

One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid

Trial Locations (14)

15213

Pfizer Investigational Site, Pittsburgh

27705

Pfizer Investigational Site, Durham

45237

Pfizer Investigational Site, Cincinnati

77040

Pfizer Investigational Site, Houston

80045

Pfizer Investigational Site, Aurora

06030

Pfizer Investigational Site, Farmington

06519

Pfizer Investigational Site, New Haven

01655

Pfizer Investigational Site, Worcester

08901

Pfizer Investigational Site, New Brunswick

T5K 2J5

Pfizer Investigational Site, Edmonton

L5M 4N4

Pfizer Investigational Site, Mississauga

M5S 2S1

Pfizer Investigational Site, Toronto

M5T 1R8

Pfizer Investigational Site, Toronto

M6J 1H4

Pfizer Investigational Site, Toronto

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00644969 - Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder | Biotech Hunter | Biotech Hunter